Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 — ULTRA-COVID  

Pneumonia, Viral Clinical Trial

Official title: Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers

Status Suspended

Clinical Trial Summary

The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral pneumonitis, requiring invasive mechanical ventilation (IMV) in an important group of patients.

In terms of preventing progression to the critical phase with the consequent need of admission to the intensive care units (ICU), it has been recently proposed that this inflammatory cytoquine-mediated process can be safely treated by a single course of ultra-low radiotherapy (RT) dose < 1 Gy.

The main purpose of the study was to analyze the efficacy of ultra low-dose pulmonary RT, as an anti-inflammatory intention in patients with SARS-Cov-2 pneumonia with a poor or no response to standard medical treatment and without IMV.

Clinical Trial Description

The exceedingly high mortality rates of severe and critical COVID-19 warrant the evaluation of novel therapies that could potentially mitigate the advanced disease manifestations. In this context, is proposes a prospective multicenter study. It will include 15 patients, to assess the feasibility and efficacy of low-dose lung irradiation in COVID-19 pneumonia. ;

Related Conditions & MeSH terms

• COVID-19
• Cytokine Release Syndrome
• Cytokine Storm
• Pneumonia
• Pneumonia, Viral

• NCT number: NCT04394182
• Study type: Interventional
• Source: Fundacion GenesisCare
• Status: Suspended
• Phase: N/A
• Start date: April 21, 2020
• Completion date: March 21, 2022